EpiCept Reports Fourth Quarter and Full Year 2012 Operating and Financial Results
February 28, 2013 00:12 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today
announced operating and financial results...
EpiCept Reports Fourth Quarter and Full Year 2012 Operating and Financial Results
February 28, 2013 00:10 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today
announced operating and financial results...
Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis
February 21, 2013 00:17 ET
|
Immune Pharmaceuticals Inc
Bertilimumab Targets Eotaxin-1, a Chemokine Over-Expressed in Ulcerative Colitis
Patients
and executive officers of EpiCept is also included in EpiCept's registration
statement Post-Effective...
EpiCept Corporation and Immune Pharmaceuticals Amend Merger Agreement
February 12, 2013 00:01 ET
|
Immune Pharmaceuticals Inc
IMMUNE TO PROVIDE EPICEPT WITH UP TO $0.5 MILLION IN WORKING CAPITAL
HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y.--(BUSINESS
WIRE (http://www.businesswire.com/))-- Regulatory News:
Immune...
EpiCept Corporation to Present at the 15th BIO CEO & Investor Conference
February 06, 2013 19:02 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced
today that Robert W. Cook, Interim...
EpiCept Reports Total Shares Outstanding
January 31, 2013 17:08 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
Pursuant to the requirements of the Swedish Financial Supervisory Authority,
EpiCept Corporation (“EpiCept”) (NASDAQ...
Daniel Teper of Immune Pharmaceuticals to Present at the 6th Annual OneMedForum
January 09, 2013 17:01 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced
today that Daniel Teper, Chief...
EpiCept Reports Third Quarter 2012 Operating and Financial Results
November 14, 2012 00:06 ET
|
Immune Pharmaceuticals Inc
Conference Call Begins at 9:00 A.M. Eastern Time Today
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX:...
EpiCept to Report Third Quarter 2012 Operating and Financial Results on November 14, 2012
November 12, 2012 00:01 ET
|
Immune Pharmaceuticals Inc
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced
today that it will host a conference...
Immune Pharmaceuticals and EpiCept Corporation Agree to Merge
November 08, 2012 00:01 ET
|
Immune Pharmaceuticals Inc
HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y.--(BUSINESS
WIRE (http://www.businesswire.com/))-- Regulatory News:
Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and
EpiCept...